New addition to the already popular "miracle weight loss pill" - more effective with fewer side effects?

"Diet magic drug" Smeaglutide has just shown its edge in the market, while another rookie, Tilpotide, is ready to go. Last Sunday, Lilly announced the results of a new study at the annual meeting of the World Obesity Society: Patients who received a weekly injection of telpopeptide (Tizepatide) for 84 weeks lost an average of more than 24% of their body weight. In this study, researchers from Johns Hopkins University and other universities and Eli Lilly studied nearly 600 overweight or obese patients. They initially lost about 7 percent of their body weight during 12 weeks of weight training without taking any medication. They were then randomly assigned to receive either the maximum dose of telpotide or placebo for 72 weeks. At the end of the study, the patients taking telpotide lost an average of another 18.4 percent of their body weight, while the patients in the placebo group gained an average of about 2.5 percent of their body weight. In contrast, according to another study, patients using Novo Nordisk Ozempic and Wegovy containing selmegllutide lost an average of about 15 **percent of their weight over a similar period of time. This suggests that telpotide may be more effective than selmegraglutide in weight loss. Wall Street has also previously introduced, Tilpotide is a dual target (GIP/GLP-1) receptor agonist developed by Lilly, which reduces the patient's weight by suppressing the patient's appetite and increasing energy consumption. Tilpotide has previously been marketed as a diabetes treatment drug. Since its launch in May last year, telpotide has become the fastest drug in the history of medicine, has completely broken all the records set by the time of the listing of smaglutide. At present, Lilly is developing a weight-loss drug version of tierpotide and is waiting for FDA approval in the United States. Thomas Wadden, lead author of the study and former president of the Obesity Society, who released the results, said in a press release that patients taking telpotide also showed improvements in other health indicators, such as blood sugar, cholesterol and blood pressure. These findings further suggest that telpotide may be a highly effective drug for weight management and the treatment of related complications:> In the most recent study, patients lost an average of 64 pounds, making the results comparable to those of surgical intervention.>> For some severely obese people, telpotide may be a safe and very effective surgical alternative. ## Less Side Effects Of course, telpotide also has side effects, but the side effects of telpotide may be lighter than that of semaglutide. The results of the study showed that 80% of the users reported at least one side effect, most of which were nausea, diarrhea, constipation or vomiting-which are also common side effects of selmegraglutide. In clinical trials, 33% of patients taking the highest dose of telpotide reported nausea, compared with 44% of patients with semaglutide. Diarrhea was reported in 23% of patients with telpotide, compared with 31% of patients with selmegllutide. **Christopher McGowan, an expert in the field of obesity and a gastroenterologist, said in a previous interview with the media that the dual effects of tilpotide GLP-1 and GIP may cause fewer and milder symptoms than semaglutide:> Side effects are similar, mainly gastrointestinal side effects, and symptoms tend to be mild to moderate, and improve over time.>> It seems that the overall incidence of side effects is lower, although this is purely anecdotal, but my patients after the transition from semaglutide to telpotide are said to be better tolerated. The McGowan also stated that there have been some reports of hair loss in patients taking semaglutide or telpotide, but this is rare and not related to the drug itself, mainly due to patients eating less:> Any intervention that results in significant and potentially rapid weight loss may result in hair loss.>> The good news is that in these cases, hair loss is almost always temporary, and the most common cause is a brief pause in hair follicle growth, known as telogen effluvium. ## The "universal medicine" is resistant and long Wall Street has introduced it earlier, Combined with a series of previous experiments, * * GLP-1 has been able to deal with more than 10 kinds of diseases such as diabetes, obesity, kidney disease, dementia, Parkinson's disease, sleep apnea, NASH (nonalcoholic steatohepatitis), psoriasis, alcohol addiction, etc. * * The outside world even holds the throne of "universal medicine. However, while the market is in a carnival, the industry has poured cold water. Kavita Patel, a physician and contributor to the White House health policy who served as President Obama's director, believes that the trial results released last week are one of the strongest evidence in support of a second use of semaglutide, **but that the evidence for its use in other conditions is not strong. **Last Thursday, local time, she told the media that Simaglutide still has a long way to go to become a" panacea ".> These trials... are far less reliable than the data we have from the (Novo Nordisk) FLOW trial in patients with chronic kidney disease, sleep apnea, cardiovascular risk, and diabetes control-double-blind placebo-controlled randomized trials are very accurate.>> We still have a long way to go in this regard. * * I have seen many so-called "magic drugs" before ". **In addition, Patel believes that efficacy is only one of the major hurdles to overcome before Ozempic can be approved for conditions other than diabetes.> **We know that this drug is very effective for diabetic patients, but there are many obstacles to getting there-including cost, compliance, and prescription rates. **It is worth noting that patients who choose to use GLP-1 drugs for weight management often have to pay out of pocket because they cannot go to insurance. Now, we're seeing active employers and entire countries refusing to pay for weight loss.